ReviewFrontiers in cardiovascular medicine2023
Adipokines in atherosclerosis: unraveling complex roles.
Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Association between potassium fluctuation and in-hospital mortality in acute myocardial infarction patients: a retrospective analysis of the MIMIC-IV database.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Adipokines as Regulators of Nitric Oxide Synthase Isoforms Across Organs: Emerging Implications for Gastrointestinal Motility.International journal of molecular sciences · 2026Review
- Tissue-Specific Chemerin in Atherosclerosis.Biomolecules · 2026Review
- Association of Body Roundness Index with all-cause and cardiovascular mortality in patients with cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3: a cohort study.American heart journal plus : cardiology research and practice · 2026Article
- Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.Current obesity reports · 2026Review
- The role and therapeutic potential of purinergic signaling pathway in metabolic syndrome-related atherosclerosis.Purinergic signalling · 2026Review
- Adipokine networks in diabetic kidney disease: mechanistic insights and therapeutic implications.Lipids in health and disease · 2026Review
- Lower serum SFRP5 levels are associated with carotid atherosclerosis in patients with essential hypertension.American journal of translational research · 2026Article
- Chemerin Normal Function and Roles in Metabolic and Nonmetabolic Disorders: An Up-To-Date Comprehensive Review.Biochemistry research international · 2026Review
- Variants of Visceral Adipocytokine Genes in Obesity and Coronary Atherosclerosis: A Review.Current medicinal chemistry · 2026Review
- Research Progress on the Association Between Sarcopenic Obesity and Atherosclerosis: Current Status and Challenges.Journal of clinical medicine · 2025Review
- Endothelial Dysfunction as the Common Pathway Linking Obesity, Hypertension and Atherosclerosis.International journal of molecular sciences · 2025Review
- Metabolic and Inflammatory Adipokine Profiles in PCOS: A Focus on Adiposity, Insulin Resistance, and Atherogenic Risk.International journal of molecular sciences · 2025Article
- Inflammation-A Link Between Arterial Atherosclerotic and Venous Thromboembolic Diseases.Cells · 2025Review
- Adipokines in preeclampsia: disrupted signaling pathways and novel therapeutic strategies.European journal of medical research · 2025Review
- NOTCH Signaling Networks in Perivascular Adipose Tissue.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
- Obesity, White Adipose Tissue, and Adipokines Signaling in Male Reproduction.Molecular nutrition & food research · 2025Review
- Plasma Atrial Natriuretic Peptide Predicts Oxidized Low-Density Lipoprotein Levels in Type 2 Diabetes Mellitus Patients Independent of Circulating Adipokine and Cytokine.International journal of molecular sciences · 2025Article
- Adiponectin and Adiponectin Receptors in Atherosclerosis.Endocrine reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipokines are biologically active factors secreted by adipose tissue that act on local and distant tissues through autocrine, paracrine, and endocrine mechanisms. However, adipokines are believed to be involved in an increased risk of atherosclerosis. Classical adipokines include leptin, adiponectin, and ceramide, while newly identified adipokines include visceral adipose tissue-derived serpin, omentin, and asprosin. New evidence suggests that adipokines can play an essential role in atherosclerosis progression and regression. Here, we summarize the complex roles of various adipokines in atherosclerosis lesions. Representative protective adipokines include adiponectin and neuregulin 4; deteriorating adipokines include leptin, resistin, thrombospondin-1, and C1q/tumor necrosis factor-related protein 5; and adipokines with dual protective and deteriorating effects include C1q/tumor necrosis factor-related protein 1 and C1q/tumor necrosis factor-related protein 3; and adipose tissue-derived bioactive materials include sphingosine-1-phosphate, ceramide, and adipose tissue-derived exosomes. However, the role of a newly discovered adipokine, asprosin, in atherosclerosis remains unclear. This article reviews progress in the research on the effects of adipokines in atherosclerosis and how they may be regulated to halt its progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.